|
Marimastat
resources
DRUG INFO
Marimastat
Drug Name:
Marimastat
|
|
|
Indication: For the treatment of various cancers
Pharmacology: Used in the treatment of cancer, it is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
Mechanism Of Action: Marimastat is a hydroxamic acid, matrix metalloprotease inhibitor. It mimics the peptide structure of natural MMP substrates. It binds to matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) thereby preventing the degradation of the basement membrane by these proteases. This antiprotease action prevents the migration of endothelial cells needed to form new blood vessels. Inhibition of MMPs also prevents the entry and exit of tymor cells into existing blood cells, thereby preventing metastasis.
Drug Category: Antineoplastic Agents; ATC:L01X
Brand Names/Synonyms: BB 2516; BB 2516;; BB-2516; Marimastat; Marimastat [Usan]
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: N-[2,2-dimethyl-1-(methylcarbamoyl)propyl]-2-[hydroxy-(hydroxycarbamoyl)methyl]-4-methyl-pentanamide
Chemical Formula: C15H29N3O5
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: APRD00559
CAS Registry Number: 154039-60-8
| | |
